Why Did CNSP Stock Surge 330% Today?

• CNS Pharmaceuticals plans to use the proceeds, along with existing cash, to identify and acquire new drug candidates in neurology and oncology.
• The company is looking to out-license its legacy programs, including Berubicin and TPI-287, to treat tumors.
• The biotech firm will look to acquire or license preclinical and clinical-stage assets with clear development paths and strong commercial potential.

Shares of CNS Pharmaceuticals Inc. (CNSP) rocketed over 330% in early trade on Monday, registering their biggest ever single-day gains since implementing a 1-for-12 reverse stock split last July, as investors cheered a $22.5 million private placement to boost its acquisition strategy.

The financing includes participation from institutional healthcare investors such as ADAR1 Capital, Ikarian Capital, Stonepine Capital Management, and Nazare Partners.

The private placement involves the sale of 650,000 common shares at $2.30 each, along with pre-funded warrants tied to over 9.1 million shares. CNSP shares closed at $2.31 on Friday.

“With the proceeds from this financing, the company is now in a strong position to execute on our recently announced corporate strategy and capitalize on opportunities created by the dynamic biotech environment over the last several years,” said Rami Levin, President and CEO of CNS Pharmaceuticals.

Strategic Shift Toward Acquisitions, Licensing

CNS Pharmaceuticals plans to use the proceeds, along with existing cash, to identify and acquire new drug candidates in neurology and oncology. The company is prioritizing assets with clear development paths, strong scientific backing, and near-term catalysts.

At the same time, the firm is looking to out-license its legacy programs, including Berubicin and TPI-287, to treat tumors.

In March, CNS Pharmaceuticals announced a new growth strategy focused on building a strong pipeline in neurology and oncology. The biotech firm will look to acquire or license preclinical and clinical-stage assets, prioritizing programs with clear development paths and strong commercial potential.

How Did Retail Traders React?

Retail sentiment for CNSP on Stocktwits turned ‘extremely bullish’ from ‘neutral’ a day earlier, amid ‘extremely high’ message volumes.

One user saw $11 to $12 as a key resistance level.

However, another user expects the stock to drop “hard.”

The stock is up 70% year-to-date.

Read also: XNDU Stock Crashed 68%, But It’s Not A New Offering – Retail Traders Call It An ‘Overreaction’

For updates and corrections, email newsroom[at]stocktwits[dot]com.